These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1125 related articles for article (PubMed ID: 27208741)
21. ZnAs@SiO Huang Y; Zhou B; Luo H; Mao J; Huang Y; Zhang K; Mei C; Yan Y; Jin H; Gao J; Su Z; Pang P; Li D; Shan H Theranostics; 2019; 9(15):4391-4408. PubMed ID: 31285768 [No Abstract] [Full Text] [Related]
22. HIF-1α-induced RIT1 promotes liver cancer growth and metastasis and its deficiency increases sensitivity to sorafenib. Song Z; Liu T; Chen J; Ge C; Zhao F; Zhu M; Chen T; Cui Y; Tian H; Yao M; Li J; Li H Cancer Lett; 2019 Sep; 460():96-107. PubMed ID: 31247273 [TBL] [Abstract][Full Text] [Related]
23. Peroxiredoxin II Is Essential for Maintaining Stemness by Redox Regulation in Liver Cancer Cells. Kwon T; Bak Y; Park YH; Jang GB; Nam JS; Yoo JE; Park YN; Bak IS; Kim JM; Yoon DY; Yu DY Stem Cells; 2016 May; 34(5):1188-97. PubMed ID: 26866938 [TBL] [Abstract][Full Text] [Related]
25. HIF-1α promoted vasculogenic mimicry formation in hepatocellular carcinoma through LOXL2 up-regulation in hypoxic tumor microenvironment. Wang M; Zhao X; Zhu D; Liu T; Liang X; Liu F; Zhang Y; Dong X; Sun B J Exp Clin Cancer Res; 2017 Apr; 36(1):60. PubMed ID: 28449718 [TBL] [Abstract][Full Text] [Related]
26. Artemin is hypoxia responsive and promotes oncogenicity and increased tumor initiating capacity in hepatocellular carcinoma. Zhang M; Zhang W; Wu Z; Liu S; Sun L; Zhong Y; Zhang X; Kong X; Qian P; Zhang H; Lobie PE; Zhu T Oncotarget; 2016 Jan; 7(3):3267-82. PubMed ID: 26675549 [TBL] [Abstract][Full Text] [Related]
27. Oxytetracycline have the therapeutic efficiency in CD133 Song Y; Kim IK; Choi I; Kim SH; Seo HR Sci Rep; 2018 Oct; 8(1):16100. PubMed ID: 30382122 [TBL] [Abstract][Full Text] [Related]
28. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Ma S; Lee TK; Zheng BJ; Chan KW; Guan XY Oncogene; 2008 Mar; 27(12):1749-58. PubMed ID: 17891174 [TBL] [Abstract][Full Text] [Related]
29. The p-MYH9/USP22/HIF-1α axis promotes lenvatinib resistance and cancer stemness in hepatocellular carcinoma. Shan Q; Yin L; Zhan Q; Yu J; Pan S; Zhuo J; Zhou W; Bao J; Zhang L; Hong J; Xiang J; Que Q; Chen K; Xu S; Wang J; Zhu Y; He B; Wu J; Xie H; Zheng S; Feng T; Ling S; Xu X Signal Transduct Target Ther; 2024 Sep; 9(1):249. PubMed ID: 39300073 [TBL] [Abstract][Full Text] [Related]
30. A Novel Function for KLF4 in Modulating the De-differentiation of EpCAM Karagonlar ZF; Akbari S; Karabicici M; Sahin E; Avci ST; Ersoy N; Ates KE; Balli T; Karacicek B; Kaplan KN; Celiker C; Atabey N; Erdal E Cells; 2020 May; 9(5):. PubMed ID: 32408542 [TBL] [Abstract][Full Text] [Related]
31. Incomplete radiofrequency ablation promotes the development of CD133 Yuan CW; Wang ZC; Liu K; Liu DJ Hepatobiliary Pancreat Dis Int; 2018 Oct; 17(5):416-422. PubMed ID: 30262419 [TBL] [Abstract][Full Text] [Related]
32. The ATP-binding cassette transporter ABCF1 is a hepatic oncofetal protein that promotes chemoresistance, EMT and cancer stemness in hepatocellular carcinoma. Fung SW; Cheung PF; Yip CW; Ng LW; Cheung TT; Chong CC; Lee C; Lai PB; Chan AW; Tsao GS; Wong CH; Chan SL; Lo KW; Cheung ST Cancer Lett; 2019 Aug; 457():98-109. PubMed ID: 31100412 [TBL] [Abstract][Full Text] [Related]
33. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. Soeda A; Park M; Lee D; Mintz A; Androutsellis-Theotokis A; McKay RD; Engh J; Iwama T; Kunisada T; Kassam AB; Pollack IF; Park DM Oncogene; 2009 Nov; 28(45):3949-59. PubMed ID: 19718046 [TBL] [Abstract][Full Text] [Related]
34. Sulfasalazine attenuates evading anticancer response of CD133-positive hepatocellular carcinoma cells. Song Y; Jang J; Shin TH; Bae SM; Kim JS; Kim KM; Myung SJ; Choi EK; Seo HR J Exp Clin Cancer Res; 2017 Mar; 36(1):38. PubMed ID: 28253902 [TBL] [Abstract][Full Text] [Related]
35. Ultrasound-targeted microbubble destruction-mediated downregulation of CD133 inhibits epithelial-mesenchymal transition, stemness and migratory ability of liver cancer stem cells. Liu YM; Li XF; Liu H; Wu XL Oncol Rep; 2015 Dec; 34(6):2977-86. PubMed ID: 26370320 [TBL] [Abstract][Full Text] [Related]
36. CD133 silencing inhibits stemness properties and enhances chemoradiosensitivity in CD133-positive liver cancer stem cells. Lan X; Wu YZ; Wang Y; Wu FR; Zang CB; Tang C; Cao S; Li SL Int J Mol Med; 2013 Feb; 31(2):315-24. PubMed ID: 23233126 [TBL] [Abstract][Full Text] [Related]
37. Anticancer and Antiangiogenic Activities of Novel α-Mangostin Glycosides in Human Hepatocellular Carcinoma Cells via Downregulation of c-Met and HIF-1α. Kim SM; Han JM; Le TT; Sohng JK; Jung HJ Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32516967 [TBL] [Abstract][Full Text] [Related]
38. Aquaporin 3 maintains the stemness of CD133+ hepatocellular carcinoma cells by activating STAT3. Wang Y; Wu G; Fu X; Xu S; Wang T; Zhang Q; Yang Y Cell Death Dis; 2019 Jun; 10(6):465. PubMed ID: 31197130 [TBL] [Abstract][Full Text] [Related]
39. A Novel Small-molecule WNT Inhibitor, IC-2, Has the Potential to Suppress Liver Cancer Stem Cells. Seto K; Sakabe T; Itaba N; Azumi J; Oka H; Morimoto M; Umekita Y; Shiota G Anticancer Res; 2017 Jul; 37(7):3569-3579. PubMed ID: 28668848 [TBL] [Abstract][Full Text] [Related]
40. Annexin A3 as a potential target for immunotherapy of liver cancer stem-like cells. Pan QZ; Pan K; Wang QJ; Weng DS; Zhao JJ; Zheng HX; Zhang XF; Jiang SS; Lv L; Tang Y; Li YQ; He J; Liu Q; Chen CL; Zhang HX; Xia JC Stem Cells; 2015 Feb; 33(2):354-66. PubMed ID: 25267273 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]